Foamix Pharmaceuticals

February 21, 2020

Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus

Gilead and Galapagos's filgotinib might not be a match for Rinvoq in ulcerative colitis, while Menlo needs to prove serlopitant works after previous setbacks.

Foamix Pharmaceuticals

Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus

US FDA approval tracker: October

Go or no go? Novartis eyes a big new growth driver

Perseverance pays off for Foamix

Dermira in a spot of bother after acne failure

Upcoming events – Another SGLT2 approval due and stem cell data for Mesoblast

Strong small cap performance drives second-quarter gains

Mid-cap biopharma stocks pick up in the first quarter

Interview – Foamix spots dermatology opportunity

Snippet roundup: Wins for AcelRx, Foamix and SGLT2 developers.

IPOs surge in Q3 as investor enthusiasm shows no sign of waning

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

Evaluate Vantage 2021 Preview

Editor's Picks

2020 wins top of the froths for biotech stocks

Biotech flotations remain in high demand

Glaxo’s growth problem

Go or no go? Oncology decisions ahead for the FDA

Pfizer reveals its PD-1 secret